In:
Antioxidants, MDPI AG, Vol. 10, No. 6 ( 2021-05-25), p. 845-
Abstract:
Ischaemic renal disease as result of atherosclerotic renovascular disease activates a complex biological response that ultimately leads to fibrosis and chronic kidney disease. Large randomised control trials have shown that renal revascularisation in patients with atherosclerotic renal artery disease does not confer any additional benefit to medical therapy alone. This is likely related to the activation of complex pathways of oxidative stress, inflammatory cytokines and fibrosis due to atherosclerotic disease and hypoxic injury due to reduced renal blood flow. New evidence from pre-clinical trials now indicates a role for specific targeted therapeutic interventions to counteract this complex pathogenesis. This evidence now suggests that the focus for those with atherosclerotic renovascular disease should be a combination of revascularisation and renoprotective therapies that target the renal tissue response to ischaemia, reduce the inflammatory infiltrate and prevent or reduce the fibrosis.
Type of Medium:
Online Resource
ISSN:
2076-3921
DOI:
10.3390/antiox10060845
Language:
English
Publisher:
MDPI AG
Publication Date:
2021
detail.hit.zdb_id:
2704216-9
SSG:
15,3
Permalink
